TABLE 4.

Change from baseline of mean FACE-Q scores used in botulinum toxin-A studies

ARTICLE		Schlessinger, 2021 Derm Surg23	Ascher, 2019 Aesth Surg J24	Cohen, 2020 Derm Surg25		Chang, 2016 Aesth Surg Journal26
PRODUCT AND UNITS (U) USED		ABO 50 U at baseline & retreatment 6 months (n= 120)	ABO 50 U (n=125)	ABO 2.5 mL reconstitution (n=30)	ABO 1.5 mL reconstitution (n=30)	ONA (20 U) (n= 16)	ABO (60 U) (n=17)	INCO (20 U) (n=18)
FOLLOW UP		Month 12 s/p 2 treatments 6 months apart	Least square mean changes from baseline Month 6 s/p single treatment	Day 120 s/p single treatment	Day 120 s/p single treatment	Week 2 s/p single treatment	Week 2 s/p single treatment	Week 2 s/p single treatment
CHANGE FROM BASELINE OF MEAN FACE-Q SCORE	APPRAISAL OF LINES	13-53.9 (range)	NR	30*	34*	NR	NR	NR
	PSYCHOLOGICAL FUNCTIONING	4-11.6 (range)	3.5*	19*	25*	NR	NR	NR
	SATISFACTION WITH APPEARANCE	NR	9.5* (24.5% increase)	NR	NR	28.9% increase	18.3% increase	36% increase
	AGE APPRAISAL VAS	NR	0.75 yrs younger*	2.2 yrs younger*	2.0 yrs younger*	-5.6 †
	SATISFACTION WITH AGE	NR	NR	NR	NR	19% increase	35% increase	34% increase

All studies injected product into the glabella.

*Significant (p<0.05) compared to baseline.

†Reported as overall percent change in age appraisal, individual changes in age appraisal not reported. ABO: AbobotulinumtoxinA; INCO: IncobotulinumtoxinA; NR: Not reported; ONA: Onabotulinum toxin A